Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Brain Neoplasms 23Lung Neoplasms 17Neoplasm Metastasis 15Breast Neoplasms 12Melanoma 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Neoplasms 3NSCLC 3Meningioma 3Gastrointestinal Neoplasms 3Unresectable Locally Recurrent Rectal Cancer 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Spinal Cord Compression 2Small Cell Lung Carcinoma 2Sarcoma 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Epidural Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Etoposide 2Carboplatin 2tivozanib 1repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Leucovorin 1Immunoglobulin G 1IFL protocol 1Fluorouracil 1Disulfides 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Radiosurgery × 90 days × Clear all
NCT03110978 2026-04-16

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
140 enrolled
EndocrineThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡